Pub Date : 2024-06-10DOI: 10.1136/dtb.2024.e254736rep
Indira Acharya, David S Weisman, Lanaya Williams Smith, Lois Johanna Arend
{"title":"Diagnostic dilemma: drug-induced vasculitis versus systemic vasculitis.","authors":"Indira Acharya, David S Weisman, Lanaya Williams Smith, Lois Johanna Arend","doi":"10.1136/dtb.2024.e254736rep","DOIUrl":"https://doi.org/10.1136/dtb.2024.e254736rep","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141300337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
### What you need to know Alopecia areata is an autoimmune disease against hair follicles, characterised by hair loss of the scalp, face and/or body, with nail involvement (eg, pitting or ridging) in 10–15% of cases.1–3 Human skin biopsy specimens from people with alopecia areata show the overexpression of Janus kinase 3 (JAK3) and, to a lesser extent, JAK1 and JAK2, which are involved in promoting inflammation via T cells and cytokines.4 The prevalence of alopecia areata has been estimated as 0.6% in Europe.5 6 In the UK, the annual incidence was found to be highest in people aged 25–29 years (5.1 per 10 000 males and 4.3 per 10 000 females) and then decreased with age.7 It can affect all ages, races and genders.5 People of Asian ethnicity, and from socially deprived and urban areas are more likely to present with alopecia areata.7 A family history of the condition, or chromosomal disorders such as Down syndrome, may increase the risk of alopecia areata,3 and it may be associated with other autoimmune diseases such as thyroiditis, type 1 diabetes and rheumatoid arthritis.8 It may be a self-limiting condition, especially in the early stages or where there is <25% hair loss. …
{"title":"▼Ritlecitinib for severe alopecia areata","authors":"BMJ Publishing Group Ltd","doi":"10.1136/dtb.2024.000014","DOIUrl":"https://doi.org/10.1136/dtb.2024.000014","url":null,"abstract":"### What you need to know Alopecia areata is an autoimmune disease against hair follicles, characterised by hair loss of the scalp, face and/or body, with nail involvement (eg, pitting or ridging) in 10–15% of cases.1–3 Human skin biopsy specimens from people with alopecia areata show the overexpression of Janus kinase 3 (JAK3) and, to a lesser extent, JAK1 and JAK2, which are involved in promoting inflammation via T cells and cytokines.4 The prevalence of alopecia areata has been estimated as 0.6% in Europe.5 6 In the UK, the annual incidence was found to be highest in people aged 25–29 years (5.1 per 10 000 males and 4.3 per 10 000 females) and then decreased with age.7 It can affect all ages, races and genders.5 People of Asian ethnicity, and from socially deprived and urban areas are more likely to present with alopecia areata.7 A family history of the condition, or chromosomal disorders such as Down syndrome, may increase the risk of alopecia areata,3 and it may be associated with other autoimmune diseases such as thyroiditis, type 1 diabetes and rheumatoid arthritis.8 It may be a self-limiting condition, especially in the early stages or where there is <25% hair loss. …","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141172920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Update patients on gonadal and fetal shielding for diagnostic imaging.","authors":"Joanna Girling","doi":"10.1136/dtb.2024.000004","DOIUrl":"10.1136/dtb.2024.000004","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"82"},"PeriodicalIF":0.0,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140943712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
### Key points Analysis of data from the Disclosure UK database shows that more than 90% of NHS trusts in England received non-research-related payments from pharmaceutical companies between 2015 and 2018.1 The authors of the study used data from the Disclosure UK database (https://search.disclosureuk.org.uk/) which contains details of payments and benefits in kind made by the pharmaceutical industry to organisations and health professionals in the UK.1 Information relating to payments made during 4 years …
{"title":"Pharmaceutical company payments to NHS trusts","authors":"BMJ Publishing Group Ltd","doi":"10.1136/dtb.2024.000031","DOIUrl":"https://doi.org/10.1136/dtb.2024.000031","url":null,"abstract":"### Key points Analysis of data from the Disclosure UK database shows that more than 90% of NHS trusts in England received non-research-related payments from pharmaceutical companies between 2015 and 2018.1 The authors of the study used data from the Disclosure UK database (https://search.disclosureuk.org.uk/) which contains details of payments and benefits in kind made by the pharmaceutical industry to organisations and health professionals in the UK.1 Information relating to payments made during 4 years …","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140883239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
### Key messages In children with acute sinusitis, antibiotic treatment had minimal benefit on symptom burden and duration, and the effect did not differ between those with and without coloured nasal discharge.1 This double-blind randomised placebo-controlled trial took place in primary care centres in the USA and involved 510 children aged 2–11 years with persistent or worsening symptoms of acute sinusitis and who scored ≥9 on the Pediatric Rhinosinusitis Symptom Scale …
{"title":"Reducing antibiotic use for acute sinusitis in children","authors":"BMJ Publishing Group Ltd","doi":"10.1136/dtb.2024.000029","DOIUrl":"https://doi.org/10.1136/dtb.2024.000029","url":null,"abstract":"### Key messages In children with acute sinusitis, antibiotic treatment had minimal benefit on symptom burden and duration, and the effect did not differ between those with and without coloured nasal discharge.1 This double-blind randomised placebo-controlled trial took place in primary care centres in the USA and involved 510 children aged 2–11 years with persistent or worsening symptoms of acute sinusitis and who scored ≥9 on the Pediatric Rhinosinusitis Symptom Scale …","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"89 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140831897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
### Key messages A recently published coroner’s report has highlighted concerns that there may be a lack of awareness over the risks associated with an overdose of propranolol.1 A patient who had a history of mental illness was prescribed an antidepressant for anxiety and to help with sleep.1 He also had a history of suicidal ideation and had made previous suicide attempts. After he was discharged from the community mental health team, he consulted his general practitioner (GP) about symptoms of anxiety and physical symptoms including …
{"title":"Increasing awareness of the risk of death from a propanolol overdose","authors":"BMJ Publishing Group Ltd","doi":"10.1136/dtb.2024.000030","DOIUrl":"https://doi.org/10.1136/dtb.2024.000030","url":null,"abstract":"### Key messages A recently published coroner’s report has highlighted concerns that there may be a lack of awareness over the risks associated with an overdose of propranolol.1 A patient who had a history of mental illness was prescribed an antidepressant for anxiety and to help with sleep.1 He also had a history of suicidal ideation and had made previous suicide attempts. After he was discharged from the community mental health team, he consulted his general practitioner (GP) about symptoms of anxiety and physical symptoms including …","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140832064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
### Key learning points A registry-based study has reinforced the need for safety warnings against using valproate during pregnancy because of an increased risk of early-onset developmental disorders in exposed children.1 This prospective cohort study used data on live-born singleton children of mothers with epilepsy from five Nordic countries to examine the association between prenatal use of antiepileptic medication and psychiatric and developmental disorders in exposed offspring.1 Children were followed up from birth until the …
{"title":"Prenatal use of antiepileptic drugs and childhood psychiatric disorders","authors":"BMJ Publishing Group Ltd","doi":"10.1136/dtb.2024.000026","DOIUrl":"https://doi.org/10.1136/dtb.2024.000026","url":null,"abstract":"### Key learning points A registry-based study has reinforced the need for safety warnings against using valproate during pregnancy because of an increased risk of early-onset developmental disorders in exposed children.1 This prospective cohort study used data on live-born singleton children of mothers with epilepsy from five Nordic countries to examine the association between prenatal use of antiepileptic medication and psychiatric and developmental disorders in exposed offspring.1 Children were followed up from birth until the …","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140809356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cytisine for smoking cessation.","authors":"","doi":"10.1136/dtb.2024.000009","DOIUrl":"https://doi.org/10.1136/dtb.2024.000009","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"10 7","pages":"71-76"},"PeriodicalIF":0.0,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140658387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The BNF is jointly published by the Royal Pharmaceutical Society and BMJ. BNF is published in print twice a year and interim updates are issued and published monthly in the digital versions. The following summary provides a brief description of some recent key changes that have been made to BNF content.
{"title":"Recent updates from the <i>BNF</i> (<i>BNF</i> 87).","authors":"","doi":"10.1136/dtb.2024.000018","DOIUrl":"10.1136/dtb.2024.000018","url":null,"abstract":"<p><p>The BNF is jointly published by the Royal Pharmaceutical Society and BMJ. BNF is published in print twice a year and interim updates are issued and published monthly in the digital versions. The following summary provides a brief description of some recent key changes that have been made to BNF content.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"68-70"},"PeriodicalIF":0.0,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140189589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：